MARKET

NAVB

NAVB

Navidea Biopharm
AMEX
0.2700
+0.0227
+9.18%
After Hours: 0.2600 -0.01 -3.70% 18:30 12/01 EST
OPEN
0.2473
PREV CLOSE
0.2473
HIGH
0.2700
LOW
0.2400
VOLUME
112.14K
TURNOVER
0
52 WEEK HIGH
1,120.70
52 WEEK LOW
0.2000
MARKET CAP
8.74M
P/E (TTM)
-0.4728
1D
5D
1M
3M
1Y
5Y
Reported Late Wednesday, Navidea Biopharmaceuticals Files Appeal In CRG Case
Benzinga · 23h ago
Navidea Biopharmaceuticals Files Appeal in CRG Case
DUBLIN, Ohio, December 01, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 202...
Business Wire · 1d ago
Navidea Biopharmaceuticals Announces 50th Participant Enrolled In The Company's Phase 3 Trial In Rheumatoid Arthritis
Benzinga · 3d ago
Notable earnings after Tuesday's close
Seekingalpha · 11/14 22:35
BRIEF-Navidea Biopharmaceuticals Reports Q3 Financial Results
Reuters · 11/14 18:16
Navidea Biopharm GAAP EPS of -$0.25, revenue of $0.08M
Seekingalpha · 11/14 13:47
Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
DUBLIN, Ohio, November 14, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results fo...
Business Wire · 11/14 13:00
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
DUBLIN, Ohio, October 05, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that results from the Com...
Business Wire · 10/05 20:30
More
About NAVB
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. Its business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. The Company has developed processes for producing the first two therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which targets activated CD206+ macrophages, and the Manocept dexamethasone (MAN-DEX) series, which inhibits the inflammatory activity of activated CD206+ macrophages.

Webull offers kinds of Navidea Biopharmaceuticals Inc stock information, including AMEX:NAVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAVB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NAVB stock methods without spending real money on the virtual paper trading platform.